BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia
Decision highlights the promise of BGB-16673, an investigational and potentially first-in-class BTK degrader designed to overcome resistance and deepen responses in B-cell malignancies
Article content
SAN CARLOS, Calif. — BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to the Company's investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of patients with Waldenstrom's macroglobulinemia (WM) previously treated with a BTK inhibitor.
Article content
'This is the Company's first PRIME designation, marking a milestone for BeOne and providing early and enhanced interaction with the EMA as we advance BGB-16673,' said Julie Lepin, Senior Vice President, Chief Regulatory Affairs Officer at BeOne. 'PRIME allows us to align early with the EMA on key evidence requirements and potentially accelerate our path to marketing authorization of BGB-16673 for patients with relapsed or refractory Waldenstrom's macroglobulinemia.'
Article content
In addition to the PRIME designation, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the EU Orphan Drug Designation (ODD) application for BGB-16673 in WM. A final decision is anticipated in the coming weeks. The U.S. Food and Drug Administration (FDA) also granted Fast Track Designation to BGB-16673 for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL).
Article content
The EMA's CHMP granted PRIME designation to BGB-16673 based on data demonstrating its novel mechanism and anti-tumor activity in B-cell malignancies. The CHMP recognized the limited treatment options available for WM patients post-BTK inhibitor therapy and acknowledged the strong biological rationale and promising clinical data for BGB-16673 in this setting, thereby demonstrating the potential to address the unmet medical need.
Article content
The PRIME initiative, launched by the EMA in 2016, provides early, proactive, and enhanced regulatory support to developers of promising medicines. It is designed to optimize development plans and accelerate evaluation, helping innovative therapies reach patients with unmet medical needs faster.
Article content
About BGB-16673
Article content
BGB-16673 is an orally available Bruton's tyrosine kinase (BTK) targeting protein degrader from BeOne's chimeric degradation activation compound (CDAC) platform. BGB-16673 is designed to promote the degradation, or breakdown, of both wild-type and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease. BGB-16673 is the most advanced BTK protein degrader in the clinic, with an extensive global clinical development program.
Article content
About BeOne Medicines
Article content
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.
Article content
Forward-Looking Statement
Article content
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's advancement of, and anticipated clinical development, regulatory milestones and commercialization of BGB-16673; the potential of BGB-16673 to significantly address the unmet medical need; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.
Article content
Article content
Article content
Article content
Contacts
Article content
Investor Contact
Article content
Article content
Liza Heapes
Article content
Article content
+1 857-302-5663
Article content
Article content
ir@beonemed.com
Article content
Media Contact
Article content
Article content
Kyle Blankenship
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
Trump and Carney to meet in the coming days, but how close is a Canada-U.S. trade deal?
The Canada-U.S. trade minister Dominic LeBlanc says the two leaders will meet in the coming days, but can trade deal be reached? CTV's Colton Praill reports.
Japan Forward
5 hours ago
- Japan Forward
Do Not Open Japan-US Trade Deal to Distorted Interpretation
このページを 日本語 で読む A trade deal was concluded by the Shigeru Ishiba administration and the Donald Trump administration. But, were the provisions of the agreement actually finalized? It is difficult to dispel doubts on that score. There are stark differences in how the Japanese and US sides explain provisions on new investment in the United States. This is a cause for concern in the actual implementation of the agreement. One of the main pillars of the Japan-US agreement sets reciprocal tariffs and auto tariffs the US imposes on Japanese imports at 15%. However, no written agreement has been drawn up. Isn't that the cause of the differences in perception between the two sides? Prime Minister Shigeru Ishiba should have spoken directly with President Trump immediately after the agreement was reached to share his views. His failure to do so has created a major problem. If things continue as they are, it is possible that the US side will try to force its own interpretation on Japan. If that were to happen, Japan's national interest might well suffer damage. The Prime Minister and Minister for Economic Revitalization Ryosei Akazawa should clarify the reasons for these differing perceptions during the extraordinary Diet session that convened on August 1. They have a duty to explain to the satisfaction of the Japanese people that the agreement will be appropriately implemented. US President Donald Trump speaks at the White House on July 31 (©Reuters via Kyodo) Regarding Japanese investment in the United States, Trump posted on social media that Japan will invest $550 billion USD (approximately ¥80 trillion JPY) in the United States. Furthermore, he said, the US will receive 90% of the profits. In response, the Japan side has explained that the $550 billion in question is actually the upper limit for investments, loans, and loan guarantees. Of this, the "90%" of the profits the US would stand to make from the deal are from investment projects. That amounts to just 1% to 2% of the $550 billion, according to Akazawa. As for the issue of rice, the US side claims that Japan's imports of American rice will increase by 75%. However, Japan has not provided any specific details. Won't this really amount to sacrificing Japan's agricultural sector? US Treasury Secretary Scott Bessent has also declared that he intends to review Japan's compliance with the agreement quarterly. He has further threatened that tariffs will be raised to 25% if Trump is not satisfied. That would provide leeway for Trump to unilaterally scrap the agreement. The lack of a joint document sharing a mutual understanding of what the agreement entails has left a legacy of problems. The Japanese side prioritized an early conclusion to the talks. That allowed the delay of the time-consuming task of hammering out a written agreement. Their excuse was to avoid a situation where an agreement could not be reached by the Trump-imposed deadline of August 1. On that date, Trump's reciprocal tariffs on Japan were scheduled to rise to 25%. Even if that is true, it will end up counterproductive if the agreement comes to be distorted by the US interpretation. Above all, the Ishiba government should urge the Trump administration to quickly align their respective views. We should realize that, unless both sides share a mutual understanding, economic uncertainty from Trump's tariffs will not dissipate. Author: Editorial Board, The Sankei Shimbun このページを 日本語 で読む
The Province
6 hours ago
- The Province
U.S. trade frameworks create 'shifting landscape' as B.C. looks to cultivate LNG markets
The U.S. is also willing to 'simply use their influence to bully trade partners into beneficial trade deals on energy,' says one observer. At the same time Premier David Eby was touting B.C.'s potential to export liquefied natural gas to Asia, U.S. President Donald Trump was unveiling his county's trade framework agreement with South Korea. Here, Eby tours the control room for the LNG Canada plant in Kitimat. Photo by Government of B.C. At the same time Premier David Eby was touting B.C.'s potential to export liquefied natural gas to Asia, U.S. President Donald Trump was unveiling his county's trade framework agreement with South Korea, which included a commitment to purchase US$100 billion of American LNG. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Tying energy to easing up on tariff threats has become a common theme in Trump's attempt to reorder the U.S. trading landscape, either with purchase commitments or contributions to American energy infrastructure, an element in a framework reached with Japan. Such agreements create a 'shifting landscape' for the LNG market that Canada will have to navigate with partners apparently willing to pay premiums for American energy in exchange for their 'strategic partnership' with the U.S., said University of B.C. trade economist Werner Antweiler. Eby's Asia trade mission, mere weeks before the U.S. deals were announced, sought to cultivate B.C.'s trade relationship with both countries, and he left sounding assured about the province's potential. Stay on top of the latest real estate news and home design trends. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. Eby spoke about meetings B.C. representatives had with LNG Canada's key partners: the Korean gas utility KOGAS, Mitsubishi in Japan and Malaysia's Petronas, where executives 'underlined how important it was to them that this project was able to be reliable.' However, Antweiler, chair in international trade policy at UBC's Sauder School of Business, noted that the U.S. is also willing to 'simply use their influence to bully trade partners into beneficial trade deals on energy. David Eby has spoken about meetings B.C. representatives had with LNG Canada's key partners: the Korean gas utility KOGAS, pictured here, Mitsubishi in Japan and Malaysia's Petronas. However, the U.S. is also willing to 'simply use their influence to bully trade partners into beneficial trade deals on energy,' says one observer. Photo by SeongJoon Cho / Bloomberg 'Some have called it a protection racket,' Antweiler said. 'Korea buys U.S. energy at a premium or preferentially, and in turn U.S. provides military protection, rather than for the U.S.'s own geostrategic benefit.' LNG's buyers — major utility firms — purchase fuel on long-term contracts and Antweiler said it is likely the South Korea deal will result in a 'reshuffling market share,' with new U.S. imports replacing its expiring contracts with Qatari LNG suppliers. This advertisement has not loaded yet, but your article continues below. 'Their overall demand for LNG is not increasing much and is down from a peak in 2021,' Antweiler said. In rough estimate, he estimated it could increase the U.S. share of South Korea's market to about one third from five per cent now. In the case of Japan, the notice from Trump's White House dated July 23, said the sides are 'exploring a new offtake agreement for Alaskan LNG,' with a proposal that is in its early stages, but which is vying for the same market share as B.C. 'Japan's commitment to Alaskan LNG may be looked at through the perspective of energy security too,' Antweiler said. Premier David Eby (right) watches as a LNG carrier manoeuvres in Kitimat. LNG Canada, a consortium of five partners including Shell, Malaysian state-owned Petronas, PetroChina, Mitsubishi Corp. and KOGAS, is contemplating a $30-billion addition to its Kitimat plant that would nearly double its capacity to 26 million tonnes of LNG per year from 14 million tonnes per year now. Photo by Government of B.C. / Government of B.C. Energy Minister Adrian Dix argued that the LNG projects in the works 'have real advantages over other projects, say the Alaska project, and everything else.' This advertisement has not loaded yet, but your article continues below. 'Obviously we only control what we control, the provincial and the federal government,' Dix said. However, he added that the provincial and federal governments are 'working closely' with LNG Canada related to the company's yet-to-be approved Phase 2. LNG Canada, a consortium of five partners including Shell, Malaysian state-owned Petronas, PetroChina, Mitsubishi Corp. and KOGAS, is contemplating a $30-billion addition to its Kitimat plant that would nearly double its capacity to 26 million tonnes of LNG per year from 14 million tonnes per year now. A spokesperson for LNG Canada said the company itself isn't involved in sales: its joint-venture partners determine where the product is delivered and sold. This advertisement has not loaded yet, but your article continues below. Dix, however, said 'we feel that our (LNG Canada Phase 2) is a really outstanding project and we're optimistic about it. But at the same time, it's not entirely our decision. It is a reason why you want to settle all the issues so that the sooner they move forward, the better it is for B.C. and for everybody.' Dix added that before now, B.C. didn't have the option of offshore exports for natural gas, the province's biggest export commodity, worth $16 billion in trade in 2024. And the U.S. trade deals underline the importance for B.C. to diversify. 'If you ask me, do I worry? I worry every day about everything,' Dix said. 'Because there's a lot at stake for B.C. and we've got to continue to meet our economic goals, we've got to continue to create more wealth and energy sovereignty.' Antweiler said Canada might need to turn to 'countries that are not constrained by trade deals with the United States.' 'It's all a matter of reshuffling trade directions, but in the end the LNG market is global,' he added. 'World supply and world demand must be clear, no matter what the U.S. does.' depenner@ Read More News News Tennis News News
